Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction

European Heart Journal

Volumn 33, Issue 3, 2012, Pages 314-324

  Lowrie, Richard ^a   Mair, Frances S ^b   Greenlaw, Nicola ^b   Forsyth, Paul ^a   Jhund, Pardeep S ^c   McConnachie, Alex ^b   Rae, Brian ^a   McMurray, John J V ^c  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Blocker; ACE inhibitor; Left ventricular systolic dysfunction; Primary care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; CAUSE OF DEATH; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE SYSTOLIC DYSFUNCTION; HOSPITAL ADMISSION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACIST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SYSTOLIC HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMMUNITY PHARMACY SERVICES; DRUG SUBSTITUTION; FAMILY PRACTICE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84856708566     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr433     Document Type: Review

References (32)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
2. Bosch M, Wensing M, Bakx JC, van der Weijden T, Hoes AW, Grol RP. Current treatment of chronic heart failure in primary care; still room for improvement. J Eval Clin Pract 2010;16:644-650.
3. Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N. Evaluation of the management of heart failure in primary care. Fam Pract 2009;26:145-153.
4. de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Buller HR, Kamphuisen PW. Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmaco surveillance study. Eur J Heart Fail 2011;13: 489-495.
5. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: a randomised Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010;12:1300-1308.
6. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol 2008;65:303-316. (Pubitemid 351316922)
7. Koshman SL, Charrios TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure. A review of randomized trials. Arch Intern Med 2008;168:687-694. (Pubitemid 351563951)
8. Roughead EE, Barratt JD, Ramsay E, Pratt N, Ryan P, Peck R, Killer G, Gilbert AL. The effectiveness of collaborative medicine reviews in delaying time to next hos-pitalization for patients with heart failure in the practice setting: results of a cohort study. Circ Heart Fail 2009;2:424-428.
9. Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, Zivin JG, Abraham I, Palmer J, Martin JR, Kramer SS, Wunz T. US Pharmacists' effect as team members on patient care. Systematic review and meta-analyses. Med Care 2010;48:923-933.
10. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Int Med 1999;159:1939-1945.
11. Lowrie R, Mair FS, Greenlaw N, Forsyth P, McConnachie A, Richardson J, Khan N, Morrison D, Messow CM, Rae B, McMurray JJV. The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. Eur J Heart Fail 2011;13:917-924.
12. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). J Health Serv Res Policy 2000;5:12-16.
13. Campbell MK, Elbourne DR, Altman DG, CONSORT group. CONSORT statement: extension to cluster randomised trials. Br Med J 2004;328:702-708.
14. Gilley J. Towards rational prescribing. Br Med J 1994;308:731-732. (Pubitemid 24087427)
15. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JWT, Capewell S, McMurray JJV. Long-term trends in first hospitaliza-tion for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515-523.
16. Lewsey JD, Gillies M, Jhund PS, Chalmers JWT, Redpath A, Briggs A, Walters M, Langhorne P, Capewell S, McMurray JJV, MacIntyre K. Sex differences in incidence mortality, and survival in individuals with stroke in Scotland, 1986-2005. Stroke 2009;40:1038-1043.
17. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1995; 48:1441-1452.
18. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486. (Pubitemid 47572633)
19. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie B, Ryden L, Thygesen K, Uretsky BF, on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
20. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler M, Hershberger RE, Spencer K, Nahara KA, Ingersoll H, Kreuger S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816. (Pubitemid 26411745)
21. Spence D, Johnson C, Berry C, Maxwell F, Lowrie R, Blue L. Establishment of a disease register for patients with LVSD in primary care and comparison of current practice with evidence-based guidelines. Pharm J 2002;268:911-913. (Pubitemid 34732954)
22. Roland M. Linking physicians' pay to the quality of care-a major experiment in the United Kingdom. N Engl J Med 2004;351:1448-1454. (Pubitemid 39288172)
23. Campbell S, Reeves D, Kontopantelis E, Middleton E, Sibbald B, Roland M. Quality of primary care in England with the introduction of pay for performance. N Engl J Med 2007;357:181.
24. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
25. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
26. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ, National Heart Failure Audit Team for England and Wales. The national heart failure audit for England and Wales 2008-2009. Heart 2011;97:876-886.
27. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980-1999: the end of an epidemic? Heart 2002;87:75-76. (Pubitemid 34074960)
28. Levy D, Kenchaiah S, Larson MG, Emelia BJ, Kupka MJ, Kalon KL, Murab M, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402. (Pubitemid 35239711)
29. Schaufelberger M, Swedberg K, Kö ster M, Rosén M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004; 25:300-307. (Pubitemid 38295438)
30. Teng TH, Finn J, Hobbs M, Hung J. Heart failure: incidence, case fatality, and hos-pitalization rates in Western Australia between 1990 and 2005. Circ Heart Fail 2010;3:236-243.
31. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail 2011;13:142-147.
32. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail 2008;1:91-97.